Q3-FY26 · A.K. Jain
Our domestic business for Q3 FY26 has delivered a growth of around 12% for the quarter.
IPCALABORATORIES / language trends
Read confidence between the lines.
IPCA Laboratories · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · A.K. Jain
Our aim is to reach EBITDA margin to begin with around 15% maybe in 2-3 years time and gradually improve it to about 20%.
Q3-FY26 · Harish Kamath
We have about 35 registrations out of which five we have commercialized. Another five to seven molecule will get commercialized over next 12 to 15 months.